Monopar Therapeutics Inc. with ticker code (MNPR) now have 3 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 40 and 11 and has a mean target at 30.33. Now with the previous closing price of 5.64 this indicates there is a potential upside of 437.8%. The day 50 moving average is 5.06 and the 200 day moving average is 6.05. The market capitalisation for the company is $69m. Find out more information at: http://www.monopartx.com
Monopar Therapeutics Inc., a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase III for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and MNPR-101, a humanized monoclonal antibody for treating advanced solid cancers. The company has a collaboration Grupo EspaÃ±ol de InvestigaciÃ³n en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19. Monopar Therapeutics Inc. was founded in 2014 and is headquartered in Wilmette, Illinois.